Spiramycin resistance in human periodontitis microbiota
The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated in the United States. Subgingival plaque specimens from 37 consecutive adults with untreated severe periodontitis were anaerobi...
Gespeichert in:
| Veröffentlicht in: | Anaerobe 2011-08, Vol.17 (4), p.201-205 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 205 |
|---|---|
| container_issue | 4 |
| container_start_page | 201 |
| container_title | Anaerobe |
| container_volume | 17 |
| creator | Rams, Thomas E. Dujardin, Sebastien Sautter, Jacqueline D. Degener, John E. van Winkelhoff, Arie J. |
| description | The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated in the United States.
Subgingival plaque specimens from 37 consecutive adults with untreated severe periodontitis were anaerobically cultured, and isolated putative periodontal pathogens were identified to a species level. In vitro resistance to spiramycin at 4 μg/ml, amoxicillin at 8 μg/ml, and/or metronidazole at 16 μg/ml was noted when putative periodontal pathogen growth was noted on the respective antibiotic-supplemented primary culture plates.
A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal pathogens with spiramycin at 4 μg/ml in drug-supplemented primary isolation plates, as compared to 23 (62.2%) subjects with amoxicillin at 8 μg/ml, and 10 (27.0%) subjects with metronidazole at 16 μg/ml. Spiramycin in vitro resistance occurred among species of
Fusobacterium nucleatum (44.4% of organism-positive subjects),
Prevotella intermedia/nigrescens (11.1%),
Parvimonas micra (10.8%),
Streptococcus constellatus (10%),
Streptococcus intermedius (10%),
Porphyromonas gingivalis (6.7%), and
Tannerella forsythia (5.3%). Amoxicillin in vitro resistance was found in
P. intermedia/nigrescens (55.5%),
T. forsythia (15.8%),
S. constellatus (10%),
F. nucleatum (5.6%), and
P. micra (2.7%). Only
S. constellatus (70%) and
S. intermedius (40%) exhibited in vitro resistance to metronidazole. When subject-based resistance data for spiramycin and metronidazole were jointly considered, all isolated putative periodontal pathogens were inhibited in vitro by one or the other of the antibiotic concentrations, except for one strain each of
S. constellatus and
S. intermedius from one study subject. Similarly, either amoxicillin or metronidazole at the drug concentrations tested inhibited in vitro all recovered putative periodontal pathogens, except
S. constellatus in one subject.
In vitro spiramycin resistance among putative periodontal pathogens of United States origin occurred in approximately one-half of severe periodontitis patients evaluated, particularly among subgingival
F. nucleatum species. In vitro resistance patterns also suggest that therapeutic concentrations of spiramycin plus metronidazole may have potential antimicrobial efficacy in non-
Aggregatibacter actinomycetemcomitans-associated periodontitis similar to amoxicillin plus metronidazole, which may be beneficial, |
| doi_str_mv | 10.1016/j.anaerobe.2011.03.017 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_904489738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1075996411000412</els_id><sourcerecordid>896826676</sourcerecordid><originalsourceid>FETCH-LOGICAL-c423t-7d1ad305ca760a6395117f853438c633bab06a9a58beca76c85a0ba0c2d475173</originalsourceid><addsrcrecordid>eNqFkMlOwzAQQC0EomX5BeiNU8I4XnMDVWxSJQ6FszVxXHDVJMVOkfr3OJRy7WlmpDfbI-SKQk6Byttlji260FUuL4DSHFgOVB2RMYVSZLpQ_HjIlcjKUvIROYtxCQnkQpySUUFFwRUtxkTN1z5gs7W-nQQXfeyxtW6Sqs9Ng-1k7YLv6q7tfe_jpPE2rfRdjxfkZIGr6C7_4jl5f3x4mz5ns9enl-n9LLO8YH2maoo1A2FRSUDJSkGpWmjBONNWMlZhBRJLFLpyA2O1QKgQbFFzJahi5-RmN3cduq-Ni71pfLRutcLWdZtoSuBcl4rpg6QupS6kVDKRckemZ2IMbmHWwTcYtoaCGeyapdnbNYNdA8zA7zFXfys2VePq_7a9zgRc74AFdgY_go_mfZ4mSAAQw-uJuNsRLkn79i6YaL1LymsfnO1N3flDV_wAUoaXDA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>896826676</pqid></control><display><type>article</type><title>Spiramycin resistance in human periodontitis microbiota</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rams, Thomas E. ; Dujardin, Sebastien ; Sautter, Jacqueline D. ; Degener, John E. ; van Winkelhoff, Arie J.</creator><creatorcontrib>Rams, Thomas E. ; Dujardin, Sebastien ; Sautter, Jacqueline D. ; Degener, John E. ; van Winkelhoff, Arie J.</creatorcontrib><description>The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated in the United States.
Subgingival plaque specimens from 37 consecutive adults with untreated severe periodontitis were anaerobically cultured, and isolated putative periodontal pathogens were identified to a species level. In vitro resistance to spiramycin at 4 μg/ml, amoxicillin at 8 μg/ml, and/or metronidazole at 16 μg/ml was noted when putative periodontal pathogen growth was noted on the respective antibiotic-supplemented primary culture plates.
A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal pathogens with spiramycin at 4 μg/ml in drug-supplemented primary isolation plates, as compared to 23 (62.2%) subjects with amoxicillin at 8 μg/ml, and 10 (27.0%) subjects with metronidazole at 16 μg/ml. Spiramycin in vitro resistance occurred among species of
Fusobacterium nucleatum (44.4% of organism-positive subjects),
Prevotella intermedia/nigrescens (11.1%),
Parvimonas micra (10.8%),
Streptococcus constellatus (10%),
Streptococcus intermedius (10%),
Porphyromonas gingivalis (6.7%), and
Tannerella forsythia (5.3%). Amoxicillin in vitro resistance was found in
P. intermedia/nigrescens (55.5%),
T. forsythia (15.8%),
S. constellatus (10%),
F. nucleatum (5.6%), and
P. micra (2.7%). Only
S. constellatus (70%) and
S. intermedius (40%) exhibited in vitro resistance to metronidazole. When subject-based resistance data for spiramycin and metronidazole were jointly considered, all isolated putative periodontal pathogens were inhibited in vitro by one or the other of the antibiotic concentrations, except for one strain each of
S. constellatus and
S. intermedius from one study subject. Similarly, either amoxicillin or metronidazole at the drug concentrations tested inhibited in vitro all recovered putative periodontal pathogens, except
S. constellatus in one subject.
In vitro spiramycin resistance among putative periodontal pathogens of United States origin occurred in approximately one-half of severe periodontitis patients evaluated, particularly among subgingival
F. nucleatum species. In vitro resistance patterns also suggest that therapeutic concentrations of spiramycin plus metronidazole may have potential antimicrobial efficacy in non-
Aggregatibacter actinomycetemcomitans-associated periodontitis similar to amoxicillin plus metronidazole, which may be beneficial, where spiramycin is clinically available, for patients hypersensitive to amoxicillin or other beta-lactam antibiotics.</description><identifier>ISSN: 1075-9964</identifier><identifier>EISSN: 1095-8274</identifier><identifier>DOI: 10.1016/j.anaerobe.2011.03.017</identifier><identifier>PMID: 21524712</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>adults ; Amoxicillin ; Anti-Bacterial Agents - pharmacology ; anti-infective properties ; antibiotic resistance ; Bacteroides forsythus ; Drug Resistance, Bacterial ; drugs ; Female ; Fusobacterium nucleatum ; Humans ; In vitro ; Male ; Metagenome - drug effects ; Metronidazole ; Microbial Sensitivity Tests - methods ; microorganisms ; Middle Aged ; pathogens ; patients ; Periodontitis ; Periodontitis - drug therapy ; Periodontitis - microbiology ; Porphyromonas gingivalis ; Prevotella intermedia ; Spiramycin ; Spiramycin - pharmacology ; Streptococcus constellatus ; Streptococcus intermedius ; Subgingival</subject><ispartof>Anaerobe, 2011-08, Vol.17 (4), p.201-205</ispartof><rights>2011 Elsevier Ltd</rights><rights>Copyright © 2011 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c423t-7d1ad305ca760a6395117f853438c633bab06a9a58beca76c85a0ba0c2d475173</citedby><cites>FETCH-LOGICAL-c423t-7d1ad305ca760a6395117f853438c633bab06a9a58beca76c85a0ba0c2d475173</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.anaerobe.2011.03.017$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,777,781,3537,27905,27906,45976</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21524712$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rams, Thomas E.</creatorcontrib><creatorcontrib>Dujardin, Sebastien</creatorcontrib><creatorcontrib>Sautter, Jacqueline D.</creatorcontrib><creatorcontrib>Degener, John E.</creatorcontrib><creatorcontrib>van Winkelhoff, Arie J.</creatorcontrib><title>Spiramycin resistance in human periodontitis microbiota</title><title>Anaerobe</title><addtitle>Anaerobe</addtitle><description>The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated in the United States.
Subgingival plaque specimens from 37 consecutive adults with untreated severe periodontitis were anaerobically cultured, and isolated putative periodontal pathogens were identified to a species level. In vitro resistance to spiramycin at 4 μg/ml, amoxicillin at 8 μg/ml, and/or metronidazole at 16 μg/ml was noted when putative periodontal pathogen growth was noted on the respective antibiotic-supplemented primary culture plates.
A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal pathogens with spiramycin at 4 μg/ml in drug-supplemented primary isolation plates, as compared to 23 (62.2%) subjects with amoxicillin at 8 μg/ml, and 10 (27.0%) subjects with metronidazole at 16 μg/ml. Spiramycin in vitro resistance occurred among species of
Fusobacterium nucleatum (44.4% of organism-positive subjects),
Prevotella intermedia/nigrescens (11.1%),
Parvimonas micra (10.8%),
Streptococcus constellatus (10%),
Streptococcus intermedius (10%),
Porphyromonas gingivalis (6.7%), and
Tannerella forsythia (5.3%). Amoxicillin in vitro resistance was found in
P. intermedia/nigrescens (55.5%),
T. forsythia (15.8%),
S. constellatus (10%),
F. nucleatum (5.6%), and
P. micra (2.7%). Only
S. constellatus (70%) and
S. intermedius (40%) exhibited in vitro resistance to metronidazole. When subject-based resistance data for spiramycin and metronidazole were jointly considered, all isolated putative periodontal pathogens were inhibited in vitro by one or the other of the antibiotic concentrations, except for one strain each of
S. constellatus and
S. intermedius from one study subject. Similarly, either amoxicillin or metronidazole at the drug concentrations tested inhibited in vitro all recovered putative periodontal pathogens, except
S. constellatus in one subject.
In vitro spiramycin resistance among putative periodontal pathogens of United States origin occurred in approximately one-half of severe periodontitis patients evaluated, particularly among subgingival
F. nucleatum species. In vitro resistance patterns also suggest that therapeutic concentrations of spiramycin plus metronidazole may have potential antimicrobial efficacy in non-
Aggregatibacter actinomycetemcomitans-associated periodontitis similar to amoxicillin plus metronidazole, which may be beneficial, where spiramycin is clinically available, for patients hypersensitive to amoxicillin or other beta-lactam antibiotics.</description><subject>adults</subject><subject>Amoxicillin</subject><subject>Anti-Bacterial Agents - pharmacology</subject><subject>anti-infective properties</subject><subject>antibiotic resistance</subject><subject>Bacteroides forsythus</subject><subject>Drug Resistance, Bacterial</subject><subject>drugs</subject><subject>Female</subject><subject>Fusobacterium nucleatum</subject><subject>Humans</subject><subject>In vitro</subject><subject>Male</subject><subject>Metagenome - drug effects</subject><subject>Metronidazole</subject><subject>Microbial Sensitivity Tests - methods</subject><subject>microorganisms</subject><subject>Middle Aged</subject><subject>pathogens</subject><subject>patients</subject><subject>Periodontitis</subject><subject>Periodontitis - drug therapy</subject><subject>Periodontitis - microbiology</subject><subject>Porphyromonas gingivalis</subject><subject>Prevotella intermedia</subject><subject>Spiramycin</subject><subject>Spiramycin - pharmacology</subject><subject>Streptococcus constellatus</subject><subject>Streptococcus intermedius</subject><subject>Subgingival</subject><issn>1075-9964</issn><issn>1095-8274</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkMlOwzAQQC0EomX5BeiNU8I4XnMDVWxSJQ6FszVxXHDVJMVOkfr3OJRy7WlmpDfbI-SKQk6Byttlji260FUuL4DSHFgOVB2RMYVSZLpQ_HjIlcjKUvIROYtxCQnkQpySUUFFwRUtxkTN1z5gs7W-nQQXfeyxtW6Sqs9Ng-1k7YLv6q7tfe_jpPE2rfRdjxfkZIGr6C7_4jl5f3x4mz5ns9enl-n9LLO8YH2maoo1A2FRSUDJSkGpWmjBONNWMlZhBRJLFLpyA2O1QKgQbFFzJahi5-RmN3cduq-Ni71pfLRutcLWdZtoSuBcl4rpg6QupS6kVDKRckemZ2IMbmHWwTcYtoaCGeyapdnbNYNdA8zA7zFXfys2VePq_7a9zgRc74AFdgY_go_mfZ4mSAAQw-uJuNsRLkn79i6YaL1LymsfnO1N3flDV_wAUoaXDA</recordid><startdate>20110801</startdate><enddate>20110801</enddate><creator>Rams, Thomas E.</creator><creator>Dujardin, Sebastien</creator><creator>Sautter, Jacqueline D.</creator><creator>Degener, John E.</creator><creator>van Winkelhoff, Arie J.</creator><general>Elsevier Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>P64</scope></search><sort><creationdate>20110801</creationdate><title>Spiramycin resistance in human periodontitis microbiota</title><author>Rams, Thomas E. ; Dujardin, Sebastien ; Sautter, Jacqueline D. ; Degener, John E. ; van Winkelhoff, Arie J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c423t-7d1ad305ca760a6395117f853438c633bab06a9a58beca76c85a0ba0c2d475173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>adults</topic><topic>Amoxicillin</topic><topic>Anti-Bacterial Agents - pharmacology</topic><topic>anti-infective properties</topic><topic>antibiotic resistance</topic><topic>Bacteroides forsythus</topic><topic>Drug Resistance, Bacterial</topic><topic>drugs</topic><topic>Female</topic><topic>Fusobacterium nucleatum</topic><topic>Humans</topic><topic>In vitro</topic><topic>Male</topic><topic>Metagenome - drug effects</topic><topic>Metronidazole</topic><topic>Microbial Sensitivity Tests - methods</topic><topic>microorganisms</topic><topic>Middle Aged</topic><topic>pathogens</topic><topic>patients</topic><topic>Periodontitis</topic><topic>Periodontitis - drug therapy</topic><topic>Periodontitis - microbiology</topic><topic>Porphyromonas gingivalis</topic><topic>Prevotella intermedia</topic><topic>Spiramycin</topic><topic>Spiramycin - pharmacology</topic><topic>Streptococcus constellatus</topic><topic>Streptococcus intermedius</topic><topic>Subgingival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rams, Thomas E.</creatorcontrib><creatorcontrib>Dujardin, Sebastien</creatorcontrib><creatorcontrib>Sautter, Jacqueline D.</creatorcontrib><creatorcontrib>Degener, John E.</creatorcontrib><creatorcontrib>van Winkelhoff, Arie J.</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><jtitle>Anaerobe</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rams, Thomas E.</au><au>Dujardin, Sebastien</au><au>Sautter, Jacqueline D.</au><au>Degener, John E.</au><au>van Winkelhoff, Arie J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spiramycin resistance in human periodontitis microbiota</atitle><jtitle>Anaerobe</jtitle><addtitle>Anaerobe</addtitle><date>2011-08-01</date><risdate>2011</risdate><volume>17</volume><issue>4</issue><spage>201</spage><epage>205</epage><pages>201-205</pages><issn>1075-9964</issn><eissn>1095-8274</eissn><abstract>The occurrence of in vitro resistance to therapeutic concentrations of spiramycin, amoxicillin, and metronidazole was determined for putative periodontal pathogens isolated in the United States.
Subgingival plaque specimens from 37 consecutive adults with untreated severe periodontitis were anaerobically cultured, and isolated putative periodontal pathogens were identified to a species level. In vitro resistance to spiramycin at 4 μg/ml, amoxicillin at 8 μg/ml, and/or metronidazole at 16 μg/ml was noted when putative periodontal pathogen growth was noted on the respective antibiotic-supplemented primary culture plates.
A total of 18 (48.7%) subjects yielded antibiotic-resistant putative periodontal pathogens with spiramycin at 4 μg/ml in drug-supplemented primary isolation plates, as compared to 23 (62.2%) subjects with amoxicillin at 8 μg/ml, and 10 (27.0%) subjects with metronidazole at 16 μg/ml. Spiramycin in vitro resistance occurred among species of
Fusobacterium nucleatum (44.4% of organism-positive subjects),
Prevotella intermedia/nigrescens (11.1%),
Parvimonas micra (10.8%),
Streptococcus constellatus (10%),
Streptococcus intermedius (10%),
Porphyromonas gingivalis (6.7%), and
Tannerella forsythia (5.3%). Amoxicillin in vitro resistance was found in
P. intermedia/nigrescens (55.5%),
T. forsythia (15.8%),
S. constellatus (10%),
F. nucleatum (5.6%), and
P. micra (2.7%). Only
S. constellatus (70%) and
S. intermedius (40%) exhibited in vitro resistance to metronidazole. When subject-based resistance data for spiramycin and metronidazole were jointly considered, all isolated putative periodontal pathogens were inhibited in vitro by one or the other of the antibiotic concentrations, except for one strain each of
S. constellatus and
S. intermedius from one study subject. Similarly, either amoxicillin or metronidazole at the drug concentrations tested inhibited in vitro all recovered putative periodontal pathogens, except
S. constellatus in one subject.
In vitro spiramycin resistance among putative periodontal pathogens of United States origin occurred in approximately one-half of severe periodontitis patients evaluated, particularly among subgingival
F. nucleatum species. In vitro resistance patterns also suggest that therapeutic concentrations of spiramycin plus metronidazole may have potential antimicrobial efficacy in non-
Aggregatibacter actinomycetemcomitans-associated periodontitis similar to amoxicillin plus metronidazole, which may be beneficial, where spiramycin is clinically available, for patients hypersensitive to amoxicillin or other beta-lactam antibiotics.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>21524712</pmid><doi>10.1016/j.anaerobe.2011.03.017</doi><tpages>5</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1075-9964 |
| ispartof | Anaerobe, 2011-08, Vol.17 (4), p.201-205 |
| issn | 1075-9964 1095-8274 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_904489738 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | adults Amoxicillin Anti-Bacterial Agents - pharmacology anti-infective properties antibiotic resistance Bacteroides forsythus Drug Resistance, Bacterial drugs Female Fusobacterium nucleatum Humans In vitro Male Metagenome - drug effects Metronidazole Microbial Sensitivity Tests - methods microorganisms Middle Aged pathogens patients Periodontitis Periodontitis - drug therapy Periodontitis - microbiology Porphyromonas gingivalis Prevotella intermedia Spiramycin Spiramycin - pharmacology Streptococcus constellatus Streptococcus intermedius Subgingival |
| title | Spiramycin resistance in human periodontitis microbiota |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A10%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spiramycin%20resistance%20in%20human%20periodontitis%20microbiota&rft.jtitle=Anaerobe&rft.au=Rams,%20Thomas%20E.&rft.date=2011-08-01&rft.volume=17&rft.issue=4&rft.spage=201&rft.epage=205&rft.pages=201-205&rft.issn=1075-9964&rft.eissn=1095-8274&rft_id=info:doi/10.1016/j.anaerobe.2011.03.017&rft_dat=%3Cproquest_cross%3E896826676%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=896826676&rft_id=info:pmid/21524712&rft_els_id=S1075996411000412&rfr_iscdi=true |